All In Biotech

Drug Trial Radar · NCT01915498

Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation

A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation

Last checked: Nov 19, 2026Latest source record: Oct 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

345

Actual

Start

Aug 27, 2013

Primary completion

Jul 25, 2019

Study completion Oct 31, 2023

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Agios Pharmaceuticals, Inc.
First posted
Aug 5, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of Phase 1 Dose Escalation/Part 1 Expansion are: * To assess the safety and tolerability of treatment with enasidenib administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle in participants with advanced hematologic malignancies. * To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or the recommended Phase 2 dose (RP2D) of enasidenib in participants with advanced hematologic malignancies. The primary objective of Phase 2 is: • To assess the efficacy of enasidenib as treatment for participants with relapsed or refractory (R/R) acute myelogenous leukemia (AML) with an IDH2 mutation.

Conditions

  • Hematologic Neoplasms

Interventions

  • EnasidenibDrug

    Enasidenib tablets administered orally every day of 28-day treatment cycles until disease progression or unacceptable toxicities.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLT)Time frame: From time of first dose up to the end of Cycle 1; 28 days
  2. Phase 1 Dose Escalation: Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: From the first dose of investigational product (IP) up to 28 days after the last dose, up to the data cutoff date of 01 September 2017; median treatment duration in the dose escalation phase was 5.0 months (range 0.4 to 34.2 months).
  3. Phase 1 Dose Expansion: Number of Participants With Treatment Emergent Adverse EventsTime frame: From the first dose of investigational product (IP) up to 28 days after the last dose of IP up to the data cutoff date of 01 September 2017; median treatment duration in Part 1 Expansion was 5.2 months (range 0.5 to 32.8 months).
  4. Phase 2 Dose Expansion: Investigator Assessed Overall Response Rate (ORR)Time frame: Response assessments were performed every 28 days through Month 12 and every 56 days thereafter until the end of treatment; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).
  5. Phase 2 Dose Expansion: Number of Participants With Treatment Emergent Adverse EventsTime frame: From the first dose of investigational product (IP) up to 28 days after the last dose, up to the data cutoff of date of 01 September 2017; median duration of treatment exposure in Phase 2 was 5.3 months (range 0.4 to 22.5 months).
  6. Safety Follow-up: Number of Participants With Treatment Emergent Adverse EventsTime frame: From the primary analysis cut-off date of 01 September 2017 to the final analysis cut-off date of 29 July 2019, a maximum of 23 months.

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • City Of Hope

    Duarte, California

  • Stanford Cancer Center

    Stanford, California

  • University Of Colorado Cancer Center

    Aurora, Colorado

  • University of Miami Sylvester Cancer Center

    Miami, Florida

  • Florida Cancer Specialists

    Sarasota, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Northwestern University

    Chicago, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana-Farber/Mass General Brigham Cancer Care, Inc

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University

    St Louis, Missouri

  • Cornell University Weill Medical College

    New York, New York

  • Memorial Sloan-Kettering Cancer Center - NYC

    New York, New York

  • Cleveland Clinic

    Cleveland, Ohio

  • Ohio State University

    Gahanna, Ohio

  • Oregon Health and Science University OHSU

    Portland, Oregon

  • Sarah Cannon Research Institute Drug Development Unit

    Nashville, Tennessee

  • Ut Southwestern Medical Center At Dallas

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Local Institution - 202

    Bordeaux, France

  • Local Institution - 204

    Paris, France

  • Local Institution - 203

    Pessac, France

  • Local Institution - 205

    Toulouse, France

  • Local Institution - 201

    Villejuif, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.